Differential long-term effects of carvedilol on proinflammatory and antiinflammatory cytokines, asymmetric dimethylarginine, and left ventricular function in patients with heart failure

Anna B. Alfieri, Luis Briceno, Gabriele Fragasso, Roberto Spoladore, Altin Palloshi, Giorgio Bassanelli, Chiara Montano, Francesco Arioli, Amarild Cuko, Giacomo Ruotolo, Alberto Margonato

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Neuroendocrine/inflammatory and endothelial functions have been indicated as crucial for heart failure (HF) patients. We evaluated relation in HF patients among cytokines and asymmetric dimethylarginine (ADMA) and left ventricular ejection fraction (LVEF) at baseline and after long-term administration of carvedilol. Interleukin 10 (IL-10), interleukin 18 (IL-18), and ADMA were measured in 22 NYHA class II to IV HF patients at baseline and after 40 ± 14 months of carvedilol treatment. Patients were divided into 2 groups according to whether, after treatment with carvedilol, LVEF had increased at least 5% (responders) or less than 5% (non-responders). In responders (11 of 22 patients), LVEF increased from 38 ± 6% to 50 ± 7%, (P <0.001); in non-responders, it decreased from 36 ± 9% to 31 ± 6%, (P = 0.02); NYHA class significantly decreased in both groups. IL-18 decreased in responders (from 586.4 ± 128 to 183.13 ± 64.4 pg/mL; P <0.001) and in non-responders (from 529.3 ± 116.25 to 142.4 ± 58.9 pg/mL; P <0.001). IL-10 increased in responders (from 0.49 ± 0.25 to 2.01 ± 1.01 pg/mL; P <0.001) and in non-responders (from 0.64 ± 0.31 to 1.33 ± 0.59 pg/mL; P <0.001). Conversely, ADMA levels decreased only in responders (from 0.67 ± 0.16 to 0.44 ± 0.15 μmol/L; P <0.001), and an inverse correlation was observed between basal ADMA levels and changes in LVEF after treatment. In HF patients, carvedilol appears to reduce symptoms and the expression of inflammation, regardless of the LV functional response. In those patients showing improvement of LVEF, the reduction of inflammation is paralleled by a reduction of ADMA. We surmise that carvedilol could be effective at various independent levels as a result of possible pleiotropic effects of this agent.

Original languageEnglish
Pages (from-to)49-54
Number of pages6
JournalJournal of Cardiovascular Pharmacology
Volume52
Issue number1
DOIs
Publication statusPublished - Jul 2008

Fingerprint

Left Ventricular Function
Anti-Inflammatory Agents
Heart Failure
Cytokines
Stroke Volume
Interleukin-18
Interleukin-10
Inflammation
N,N-dimethylarginine
carvedilol
Therapeutics

Keywords

  • Carvedilol
  • Endothelial function
  • Heart failure
  • Inflammation

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Differential long-term effects of carvedilol on proinflammatory and antiinflammatory cytokines, asymmetric dimethylarginine, and left ventricular function in patients with heart failure. / Alfieri, Anna B.; Briceno, Luis; Fragasso, Gabriele; Spoladore, Roberto; Palloshi, Altin; Bassanelli, Giorgio; Montano, Chiara; Arioli, Francesco; Cuko, Amarild; Ruotolo, Giacomo; Margonato, Alberto.

In: Journal of Cardiovascular Pharmacology, Vol. 52, No. 1, 07.2008, p. 49-54.

Research output: Contribution to journalArticle

Alfieri, Anna B. ; Briceno, Luis ; Fragasso, Gabriele ; Spoladore, Roberto ; Palloshi, Altin ; Bassanelli, Giorgio ; Montano, Chiara ; Arioli, Francesco ; Cuko, Amarild ; Ruotolo, Giacomo ; Margonato, Alberto. / Differential long-term effects of carvedilol on proinflammatory and antiinflammatory cytokines, asymmetric dimethylarginine, and left ventricular function in patients with heart failure. In: Journal of Cardiovascular Pharmacology. 2008 ; Vol. 52, No. 1. pp. 49-54.
@article{c8b199393f1f456bbb22ec8c13b5a950,
title = "Differential long-term effects of carvedilol on proinflammatory and antiinflammatory cytokines, asymmetric dimethylarginine, and left ventricular function in patients with heart failure",
abstract = "Neuroendocrine/inflammatory and endothelial functions have been indicated as crucial for heart failure (HF) patients. We evaluated relation in HF patients among cytokines and asymmetric dimethylarginine (ADMA) and left ventricular ejection fraction (LVEF) at baseline and after long-term administration of carvedilol. Interleukin 10 (IL-10), interleukin 18 (IL-18), and ADMA were measured in 22 NYHA class II to IV HF patients at baseline and after 40 ± 14 months of carvedilol treatment. Patients were divided into 2 groups according to whether, after treatment with carvedilol, LVEF had increased at least 5{\%} (responders) or less than 5{\%} (non-responders). In responders (11 of 22 patients), LVEF increased from 38 ± 6{\%} to 50 ± 7{\%}, (P <0.001); in non-responders, it decreased from 36 ± 9{\%} to 31 ± 6{\%}, (P = 0.02); NYHA class significantly decreased in both groups. IL-18 decreased in responders (from 586.4 ± 128 to 183.13 ± 64.4 pg/mL; P <0.001) and in non-responders (from 529.3 ± 116.25 to 142.4 ± 58.9 pg/mL; P <0.001). IL-10 increased in responders (from 0.49 ± 0.25 to 2.01 ± 1.01 pg/mL; P <0.001) and in non-responders (from 0.64 ± 0.31 to 1.33 ± 0.59 pg/mL; P <0.001). Conversely, ADMA levels decreased only in responders (from 0.67 ± 0.16 to 0.44 ± 0.15 μmol/L; P <0.001), and an inverse correlation was observed between basal ADMA levels and changes in LVEF after treatment. In HF patients, carvedilol appears to reduce symptoms and the expression of inflammation, regardless of the LV functional response. In those patients showing improvement of LVEF, the reduction of inflammation is paralleled by a reduction of ADMA. We surmise that carvedilol could be effective at various independent levels as a result of possible pleiotropic effects of this agent.",
keywords = "Carvedilol, Endothelial function, Heart failure, Inflammation",
author = "Alfieri, {Anna B.} and Luis Briceno and Gabriele Fragasso and Roberto Spoladore and Altin Palloshi and Giorgio Bassanelli and Chiara Montano and Francesco Arioli and Amarild Cuko and Giacomo Ruotolo and Alberto Margonato",
year = "2008",
month = "7",
doi = "10.1097/FJC.0b013e31817e0edd",
language = "English",
volume = "52",
pages = "49--54",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Differential long-term effects of carvedilol on proinflammatory and antiinflammatory cytokines, asymmetric dimethylarginine, and left ventricular function in patients with heart failure

AU - Alfieri, Anna B.

AU - Briceno, Luis

AU - Fragasso, Gabriele

AU - Spoladore, Roberto

AU - Palloshi, Altin

AU - Bassanelli, Giorgio

AU - Montano, Chiara

AU - Arioli, Francesco

AU - Cuko, Amarild

AU - Ruotolo, Giacomo

AU - Margonato, Alberto

PY - 2008/7

Y1 - 2008/7

N2 - Neuroendocrine/inflammatory and endothelial functions have been indicated as crucial for heart failure (HF) patients. We evaluated relation in HF patients among cytokines and asymmetric dimethylarginine (ADMA) and left ventricular ejection fraction (LVEF) at baseline and after long-term administration of carvedilol. Interleukin 10 (IL-10), interleukin 18 (IL-18), and ADMA were measured in 22 NYHA class II to IV HF patients at baseline and after 40 ± 14 months of carvedilol treatment. Patients were divided into 2 groups according to whether, after treatment with carvedilol, LVEF had increased at least 5% (responders) or less than 5% (non-responders). In responders (11 of 22 patients), LVEF increased from 38 ± 6% to 50 ± 7%, (P <0.001); in non-responders, it decreased from 36 ± 9% to 31 ± 6%, (P = 0.02); NYHA class significantly decreased in both groups. IL-18 decreased in responders (from 586.4 ± 128 to 183.13 ± 64.4 pg/mL; P <0.001) and in non-responders (from 529.3 ± 116.25 to 142.4 ± 58.9 pg/mL; P <0.001). IL-10 increased in responders (from 0.49 ± 0.25 to 2.01 ± 1.01 pg/mL; P <0.001) and in non-responders (from 0.64 ± 0.31 to 1.33 ± 0.59 pg/mL; P <0.001). Conversely, ADMA levels decreased only in responders (from 0.67 ± 0.16 to 0.44 ± 0.15 μmol/L; P <0.001), and an inverse correlation was observed between basal ADMA levels and changes in LVEF after treatment. In HF patients, carvedilol appears to reduce symptoms and the expression of inflammation, regardless of the LV functional response. In those patients showing improvement of LVEF, the reduction of inflammation is paralleled by a reduction of ADMA. We surmise that carvedilol could be effective at various independent levels as a result of possible pleiotropic effects of this agent.

AB - Neuroendocrine/inflammatory and endothelial functions have been indicated as crucial for heart failure (HF) patients. We evaluated relation in HF patients among cytokines and asymmetric dimethylarginine (ADMA) and left ventricular ejection fraction (LVEF) at baseline and after long-term administration of carvedilol. Interleukin 10 (IL-10), interleukin 18 (IL-18), and ADMA were measured in 22 NYHA class II to IV HF patients at baseline and after 40 ± 14 months of carvedilol treatment. Patients were divided into 2 groups according to whether, after treatment with carvedilol, LVEF had increased at least 5% (responders) or less than 5% (non-responders). In responders (11 of 22 patients), LVEF increased from 38 ± 6% to 50 ± 7%, (P <0.001); in non-responders, it decreased from 36 ± 9% to 31 ± 6%, (P = 0.02); NYHA class significantly decreased in both groups. IL-18 decreased in responders (from 586.4 ± 128 to 183.13 ± 64.4 pg/mL; P <0.001) and in non-responders (from 529.3 ± 116.25 to 142.4 ± 58.9 pg/mL; P <0.001). IL-10 increased in responders (from 0.49 ± 0.25 to 2.01 ± 1.01 pg/mL; P <0.001) and in non-responders (from 0.64 ± 0.31 to 1.33 ± 0.59 pg/mL; P <0.001). Conversely, ADMA levels decreased only in responders (from 0.67 ± 0.16 to 0.44 ± 0.15 μmol/L; P <0.001), and an inverse correlation was observed between basal ADMA levels and changes in LVEF after treatment. In HF patients, carvedilol appears to reduce symptoms and the expression of inflammation, regardless of the LV functional response. In those patients showing improvement of LVEF, the reduction of inflammation is paralleled by a reduction of ADMA. We surmise that carvedilol could be effective at various independent levels as a result of possible pleiotropic effects of this agent.

KW - Carvedilol

KW - Endothelial function

KW - Heart failure

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=55949108230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55949108230&partnerID=8YFLogxK

U2 - 10.1097/FJC.0b013e31817e0edd

DO - 10.1097/FJC.0b013e31817e0edd

M3 - Article

VL - 52

SP - 49

EP - 54

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 1

ER -